GSK's bepirovirsen achieves 19% functional cure rate in chronic hepatitis B trials

GSK announced positive Phase 3 pivotal data for bepirovirsen, Ionis's antisense oligonucleotide, showing a 19% functional cure rate versus 0% with standard of care in chronic hepatitis B patients. The results represent significant commercial potential for Ionis through its partnership with GSK in a market affecting over 240 million people worldwide.